3 Merger and Acquisitions Stock Stories For a Thursday Appraisal

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Elan Corporation (NYSE:ELN): Current price $12.39

On Thursday, Elan announced that its board as decided that the privately-held investment firm Royalty Pharma’s revised offer as of May 20, to purchase all of Elan’s shares at $12.50 through its shell subsidiary Echo Pharma Acquisition Limited, substantially undervalues the firm. Elan Chairman Robert A. Ingram commented that “the revised offer from Royalty Pharma continues to grossly undervalue our company’s current business platform and our future prospects. This offer is no more than an opportunistic attempt to acquire our company at a substantial discount at our Shareholders’ expense. Put simply, for Royalty Pharma to win, you our Shareholders must lose. Accordingly, the Board unanimously and without reservation rejects the revised Royalty Pharma offer.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ELN

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business